KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:待检查 入排置信度 0.96

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Pau Montesinos, Rebeca Rodríguez-Veiga, Juan Miguel Bergua, Jesús Lorenzo Algarra Algarra, Carmen Botella, Eduardo Rodríguez-Arbolí, Teresa Bernal, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega, Juan Antonio López-López, Susana Vives, Jose Luis López-Lorenzo, Mercedes Colorado, Maria-Belén Vidriales, Raimundo García Boyero, Maria Teresa Olave, Pilar Herrera Puente, Olga Arce, Manuel Barrios, Maria Jose Sayas, Marta Polo, Maria Isabel Gómez-Roncero, Eva Barragán, Rosa Ayala, Carmen Chillón, Maria José Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas-Avilés, Pilar Lloret-Madrid, Maria-José Sánchez, Carlos Rodríguez-Medina, Laida Cuevas, José Ángel Raposo-Puglia, M Carmen Mateos, Matxalen Olivares, Carmen Martínez-Chamorro, Natalia Alonso, Sandra Suárez, Irene Sánchez-Vadillo, María Solé Rodríguez, Bernardo Javier González, Antonio Martínez-Francés, Rebeca Cuello, Alfonso Fernández, David Martínez-Cuadrón, Jorge Labrador, PETHEMA group, PETHEMA Group

J Clin Oncol 44(1) 42-53

PMID41082703
PMCIDPMC12736402
DOI10.1200/JCO-25-01841
发表日期2025-10-13
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
AI 判定该论文不进入自动 KM 提取:The publication explicitly describes a Phase II clinical trial, not a Phase III trial.
摘要

摘要

PURPOSE: Quizartinib, an oral, selective, second-generation, type-II FMS-like tyrosine kinase 3 (FLT3) inhibitor with high binding affinity to internal tandem duplication (ITD) and wild-type (WT) FLT3, has shown early clinical activity as monotherapy in patients with relapsed/refractory FLT3-ITD-negative AML. The phase III QuANTUM-First trial showed that quizartinib significantly prolonged survival versus placebo when added to standard chemotherapy, followed by single-agent maintenance, in patients with newly diagnosed (ND) FLT3-ITD-positive AML. We investigated the safety and efficacy of quizartinib in patients with ND FLT3-ITD-negative AML. METHODS: The phase II, randomized, double-blind, placebo-controlled QUIWI trial enrolled patients age 18-70 years with ND FLT3-ITD-negative (mutant-to-WT allelic ratio <0.03) AML. Patients were randomly assigned 2:1 to receive standard induction and consolidation chemotherapy combined with either quizartinib 60 mg once daily or placebo, followed by single-agent maintenance with quizartinib or placebo. The primary end point was event-free survival (EFS). Secondary end points included overall survival (OS) and safety. RESULTS: Overall, 273 patients were randomly assigned to quizartinib (n = 180) or placebo (n = 93). At data cutoff, median EFS was 20.4 months and 9.9 months in the quizartinib and placebo arms, respectively (P = .046). Median OS was not reached and 29.3 months in the quizartinib and placebo arms, respectively (P = .012); 3-year OS rates were 60.8% and 45.7%. The most frequently reported adverse events (any grade) were fever, rash, diarrhea, and mucositis. CONCLUSION: The addition of quizartinib to standard chemotherapy was associated with significantly longer EFS and OS than placebo in patients with ND FLT3-ITD-negative AML.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。